Even after anti-androgen therapy, docetaxel remains useful in prostate cancer

40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.
Source: ScienceDaily Headlines - Category: Science Source Type: news